Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016 | Zendy

Alan R. Katz | Zendy; Alan Y Komeya | Zendy; Robert D. Kirkcaldy | Zendy; A. Christian Whelen | Zendy; Olusegun O. Soge | Zendy; John R. Papp | Zendy; Ellen N. Kersh | Zendy; Glenn M. Wasserman | Zendy; Norman P. O’Connor | Zendy; Pamela O'Brien | Zendy; Douglas T Sato | Zendy; Eloisa V. Maningas | Zendy; Gail Y. Kunimoto | Zendy; Juval E Tomas | Zendy

Open Access

Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016

Author(s) -

Alan R. Katz,

Alan Y Komeya,

Robert D. Kirkcaldy,

A. Christian Whelen,

Olusegun O. Soge,

John R. Papp,

Ellen N. Kersh,

Glenn M. Wasserman,

Norman P. O’Connor,

Pamela O'Brien,

Douglas T Sato,

Eloisa V. Maningas,

Gail Y. Kunimoto,

Juval E Tomas

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix485

Subject(s) - ceftriaxone , azithromycin , neisseria gonorrhoeae , medicine , microbiology and biotechnology , neisseriaceae , gonococcal infection , antibiotics , virology , sexually transmitted disease , biology , syphilis , human immunodeficiency virus (hiv)

The Centers for Disease Control and Prevention (CDC) currently recommends dual therapy with ceftriaxone and azithromycin for gonorrhea to ensure effective treatment and slow emergence of antimicrobial resistance. Since 2013, the prevalence of reduced azithromycin susceptibility increased in the United States; however, these strains were highly susceptible to cephalosporins. We identified a cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance, several of which also demonstrated decreased ceftriaxone susceptibility.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research